Actavis Completes Sales Reorganization, Pipeline Rationalization
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will move forward with 70 pipeline candidates following the closing of the Allergan merger, Senior VP-Brand R&D David Nicholson said during the company’s first quarter earnings call.